Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more
Pacific Biosciences of California (PACB) - Net Assets
Latest net assets as of December 2025: $5.35 Million USD
Based on the latest financial reports, Pacific Biosciences of California (PACB) has net assets worth $5.35 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($784.08 Million) and total liabilities ($778.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.35 Million |
| % of Total Assets | 0.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -99.32% |
| 10-Year Change | -93.68% |
| Growth Volatility | 138.97 |
Pacific Biosciences of California - Net Assets Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pacific Biosciences of California (2008–2025)
The table below shows the annual net assets of Pacific Biosciences of California from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.35 Million | -98.94% |
| 2024-12-31 | $506.59 Million | -27.76% |
| 2023-12-31 | $701.30 Million | +24.59% |
| 2022-12-31 | $562.90 Million | -28.84% |
| 2021-12-31 | $790.99 Million | +135.77% |
| 2020-12-31 | $335.49 Million | +510.91% |
| 2019-12-31 | $54.92 Million | -51.85% |
| 2018-12-31 | $114.06 Million | +32.47% |
| 2017-12-31 | $86.10 Million | +1.69% |
| 2016-12-31 | $84.67 Million | +15.13% |
| 2015-12-31 | $73.54 Million | +33.83% |
| 2014-12-31 | $54.95 Million | -20.57% |
| 2013-12-31 | $69.18 Million | -36.75% |
| 2012-12-31 | $109.38 Million | -42.87% |
| 2011-12-31 | $191.46 Million | -31.59% |
| 2010-12-31 | $279.87 Million | +258.01% |
| 2009-12-31 | $-177.12 Million | -89.66% |
| 2008-12-31 | $-93.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pacific Biosciences of California's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 259100400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $302.00K | 5.65% |
| Other Comprehensive Income | $457.00K | 8.54% |
| Other Components | $2.70 Billion | 50474.71% |
| Total Equity | $5.35 Million | 100.00% |
Pacific Biosciences of California Competitors by Market Cap
The table below lists competitors of Pacific Biosciences of California ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anhui Xinhua Media Co Ltd
SHG:601801
|
$398.22 Million |
|
Lets Holding Group Co Ltd
SHE:002398
|
$398.25 Million |
|
Shanghai Ziyan Foods Co Ltd
SHG:603057
|
$398.25 Million |
|
Jiangsu Transimage Technology Co Ltd
SHE:002866
|
$398.39 Million |
|
Urban Company Limited
NSE:URBANCO
|
$398.18 Million |
|
Taiwan Puritic Corp.
TWO:6826
|
$397.98 Million |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093
|
$397.91 Million |
|
Prothena Corporation plc
NASDAQ:PRTA
|
$397.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pacific Biosciences of California's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 506,594,000 to 5,349,000, a change of -501,245,000 (-98.9%).
- Net loss of 546,376,000 reduced equity.
- Other comprehensive income increased equity by 35,000.
- Other factors increased equity by 45,096,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-546.38 Million | -10214.54% |
| Other Comprehensive Income | $35.00K | +0.65% |
| Other Changes | $45.10 Million | +843.07% |
| Total Change | $- | -98.94% |
Book Value vs Market Value Analysis
This analysis compares Pacific Biosciences of California's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 76.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-120.68 | $1.36 | x |
| 2009-12-31 | $-228.89 | $1.36 | x |
| 2010-12-31 | $10.41 | $1.36 | x |
| 2011-12-31 | $3.55 | $1.36 | x |
| 2012-12-31 | $1.96 | $1.36 | x |
| 2013-12-31 | $1.10 | $1.36 | x |
| 2014-12-31 | $0.78 | $1.36 | x |
| 2015-12-31 | $0.97 | $1.36 | x |
| 2016-12-31 | $0.95 | $1.36 | x |
| 2017-12-31 | $0.81 | $1.36 | x |
| 2018-12-31 | $0.84 | $1.36 | x |
| 2019-12-31 | $0.36 | $1.36 | x |
| 2020-12-31 | $1.92 | $1.36 | x |
| 2021-12-31 | $3.87 | $1.36 | x |
| 2022-12-31 | $2.51 | $1.36 | x |
| 2023-12-31 | $2.77 | $1.36 | x |
| 2024-12-31 | $1.76 | $1.36 | x |
| 2025-12-31 | $0.02 | $1.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pacific Biosciences of California utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10214.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -341.47%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 146.58x
- Recent ROE (-10214.54%) is below the historical average (-627.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | -4856.16% | 0.01x | 0.00x | $-34.42 Million |
| 2009 | 0.00% | -64965.19% | 0.00x | 0.00x | $-69.99 Million |
| 2010 | -50.08% | -8373.12% | 0.01x | 1.09x | $-168.15 Million |
| 2011 | -57.13% | -323.03% | 0.16x | 1.14x | $-128.53 Million |
| 2012 | -86.36% | -363.56% | 0.20x | 1.19x | $-105.40 Million |
| 2013 | -114.62% | -281.37% | 0.21x | 1.97x | $-86.21 Million |
| 2014 | -120.40% | -109.19% | 0.49x | 2.27x | $-71.65 Million |
| 2015 | -43.10% | -34.16% | 0.71x | 1.78x | $-39.05 Million |
| 2016 | -87.84% | -81.99% | 0.66x | 1.63x | $-82.84 Million |
| 2017 | -107.07% | -98.63% | 0.65x | 1.67x | $-100.80 Million |
| 2018 | -89.92% | -130.44% | 0.46x | 1.49x | $-113.97 Million |
| 2019 | -153.20% | -92.57% | 0.61x | 2.69x | $-89.63 Million |
| 2020 | 8.76% | 37.27% | 0.19x | 1.23x | $-4.15 Million |
| 2021 | -22.91% | -138.85% | 0.07x | 2.54x | $-260.32 Million |
| 2022 | -55.83% | -244.92% | 0.07x | 3.14x | $-370.54 Million |
| 2023 | -43.74% | -152.97% | 0.11x | 2.49x | $-376.87 Million |
| 2024 | -61.16% | -201.18% | 0.12x | 2.49x | $-360.51 Million |
| 2025 | -10214.54% | -341.47% | 0.20x | 146.58x | $-546.91 Million |
Industry Comparison
This section compares Pacific Biosciences of California's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $539,803,485
- Average return on equity (ROE) among peers: -52.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pacific Biosciences of California (PACB) | $5.35 Million | 0.00% | 145.58x | $398.20 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-7.40 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $3.67 Billion | 38.07% | 1.09x | $190.05 Billion |
| Acarix AB (publ) (ACIXF) | $1.44 Million | -102.09% | 0.28x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $2.76 Million | -21.69% | 0.89x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $9.28 Million | -68.70% | 0.12x | $2.76 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $1.58 Billion | 5.73% | 1.84x | $911.62 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $11.89 Million | -17.74% | 0.30x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $456.18K | -277.12% | 2.12x | $10.62 Million |